Titre:
  • Pathological complete response after neoadjuvant chemotherapy is an independent predictive factor irrespective of simplified breast cancer intrinsic subtypes: A landmark and two-step approach analyses from the EORTC 10994/BIG 1-00 phase III trial
Auteur:Bonnefoi, Herve; Litière, Saskia; Piccart-Gebhart, Martine; MacGrogan, Gaetan; Fumoleau, Pierre; Brain, Etienne; Petit, Thierry; Rouanet, Philippe; Jassem, Jacek; Moldovan, Cristian; Bodmer, Alexandre; Zaman, Khalil; Cufer, Tanja; Campone, Mario; Luporsi, Élisabeth E.; Malmström, Per Olof P.; Werutsky, Gustavo; Bogaerts, Jan; Bergh, Jonas; Cameron, David A
Informations sur la publication:Annals of oncology, 25, 6, page (1128-1136)
Statut de publication:Publié, 2014
Sujet CREF:Hématologie
Cancérologie
Mots-clés:Breast cancer
Landmark analysis
Neoadjuvant chemotherapy
Pathological complete response
TP53
MeSH keywords:Adult
Antineoplastic Combined Chemotherapy Protocols -- therapeutic use
Breast Neoplasms -- drug therapy -- metabolism -- mortality
Carcinoma, Ductal, Breast -- drug therapy -- metabolism -- mortality
Chemotherapy, Adjuvant -- mortality
Disease-Free Survival
Female
Humans
Middle Aged
Neoadjuvant Therapy -- mortality
Prognosis
Proportional Hazards Models
Treatment Outcome
Tumor Suppressor Protein p53 -- biosynthesis
Note générale:SCOPUS: ar.j
Langue:Anglais
Identificateurs:urn:issn:0923-7534
info:doi/10.1093/annonc/mdu118
info:pii/mdu118
info:scp/84903277747
info:pmid/24618153